8 results match your criteria: "Department of Radiation Oncology (MAASTRO) GROW School for Oncology and Developmental Biology[Affiliation]"

Background: The optimal treatment for patients with pathological node-positive (pN1) prostate cancer (PCa) is unclear.

Objective: To evaluate whether whole-pelvis radiotherapy (WPRT) improves clinical relapse-free survival (cRFS) in comparison to prostate-only radiotherapy (PORT) in pN1 PCa.

Design, Setting, And Participants: PROPER was a phase 3 trial randomizing patients to WPRT or PORT.

View Article and Find Full Text PDF

The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study.

Respir Res

January 2022

Department of Pharmacology and Toxicology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.

Background: Fibrotic Interstitial lung diseases (ILD) are a heterogeneous group of chronic lung diseases characterized by diverse degrees of lung inflammation and remodeling. They include idiopathic ILD such as idiopathic pulmonary fibrosis (IPF), and ILD secondary to chronic inflammatory diseases such as connective tissue disease (CTD). Precise differential diagnosis of ILD is critical since anti-inflammatory and immunosuppressive drugs, which are beneficial in inflammatory ILD, are detrimental in IPF.

View Article and Find Full Text PDF

Secretion of pro-angiogenic extracellular vesicles during hypoxia is dependent on the autophagy-related protein GABARAPL1.

J Extracell Vesicles

December 2021

Department of Radiation Oncology Radiation Oncology (Maastro) / GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre +, Maastricht, Netherlands.

Article Synopsis
  • Tumors often become low in oxygen, which helps them grow and resist treatments.
  • To fix this, tumor cells create tiny bubbles called extracellular vesicles (EVs) that help make new blood vessels for oxygen.
  • A protein called GABARAPL1 is important for making and releasing these EVs, and if it’s turned off, the tumors don’t grow as well and respond better to treatments.
View Article and Find Full Text PDF

Artificial Intelligence Applications to Improve the Treatment of Locally Advanced Non-Small Cell Lung Cancers.

Cancers (Basel)

May 2021

Department of Radiation Oncology (Maastro) GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, 6229 ET Maastricht, The Netherlands.

Locally advanced non-small cell lung cancer patients represent around one third of newly diagnosed lung cancer patients. There remains a large unmet need to find treatment strategies that can improve the survival of these patients while minimizing therapeutical side effects. Increasing the availability of patients' data (imaging, electronic health records, patients' reported outcomes, and genomics) will enable the application of AI algorithms to improve therapy selections.

View Article and Find Full Text PDF

A review on radiomics and the future of theranostics for patient selection in precision medicine.

Br J Radiol

November 2018

1 The D-Lab: Decision Support for Precision Medicine GROW - School for Oncology and Developmental Biology & MCCC , Maastricht University Medical Centre+, Maastricht , The Netherlands.

The growing complexity and volume of clinical data and the associated decision-making processes in oncology promote the advent of precision medicine. Precision (or personalised) medicine describes preventive and/or treatment procedures that take individual patient variability into account when proscribing treatment, and has been hindered in the past by the strict requirements of accurate, robust, repeatable and preferably non-invasive biomarkers to stratify both the patient and the disease. In oncology, tumour subtypes are traditionally measured through repeated invasive biopsies, which are taxing for the patient and are cost and labour intensive.

View Article and Find Full Text PDF

PET in the management of locally advanced and metastatic NSCLC.

Nat Rev Clin Oncol

July 2015

Department of Radiation Oncology, Radboud University Medical Centre, P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.

Despite considerable improvements in the treatment options for advanced-stage non-small-cell lung cancer (NSCLC), disease-specific survival remains poor. With the aim of improving patient outcome, the treatment paradigm of locally advanced NSCLC has shifted from solely radiotherapy towards combined and intensified treatment approaches. Also, treatment for patients with stage IV (oligo)metastatic NSCLC has evolved rapidly, with therapeutic options that include a number of targeted agents, surgery, and stereotactic ablative radiotherapy.

View Article and Find Full Text PDF

The DICOM standard is ubiquitous within medicine. However, improved DICOM semantics would significantly enhance search operations. Furthermore, databases of current PACS systems are not flexible enough for the demands within image analysis research.

View Article and Find Full Text PDF